Track the Maze Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €1.5bn. The latest transaction was filed on 4 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Bernstein Harold. The full history is openly available.
88
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€6m
47 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Maze Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$62.55.
51Σ signal
Buys n/a€6m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,294 of 29,062 companies
11.6
score / 100
Value
18
Quality
5
FCF yld-7.4%
Earn yld-8.6%
EV/EBITDA·
ROE-37%
Gross mgn·
Net mgn-91%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Maze Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias para enfermedades genéticas. Emplea enfoques innovadores para identificar y desarrollar tratamientos dirigidos.